Analyst Research: Actavis Inc (ACT)
ACT on New York Consolidated
125.67USD
18 Jun 2013
125.67USD
18 Jun 2013
Price Change (% chg)
$0.73 (+0.58%)
$0.73 (+0.58%)
Prev Close
$124.94
$124.94
Open
$125.22
$125.22
Day's High
$126.27
$126.27
Day's Low
$124.44
$124.44
Volume
621,683
621,683
Avg. Vol
1,602,753
1,602,753
52-wk High
$133.00
$133.00
52-wk Low
$68.57
$68.57
| Name | Age | Since | Current Position |
|---|---|---|---|
Andrew Turner |
66 | 2008 | Independent Chairman of the Board |
Paul Bisaro |
52 | 2007 | President, Chief Executive Officer, Director |
Sigurdur Olafsson |
44 | 2012 | President - Actavis Pharma |
Robert Stewart |
45 | 2012 | President - Global Operations |
G. Frederick Wilkinson |
56 | 2012 | President - Actavis Specialty Brands |
- U.S. justices say FTC can challenge deals to keep generic drugs off market
- PRESS DIGEST - Financial Times - May 21
- Actavis to buy Warner Chilcott in $5 billion stock deal
- UPDATE 4-Actavis to buy Warner Chilcott in $5 billion stock deal
- CORRECTED-UPDATE 1-Actavis to buy Warner Chilcott in $5 billion stock deal
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
